The current financial score of Transmedics Group Inc is 8.64. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 189.95M, representing a year-over-year increase of 20.70%, while its net profit experienced a year-over-year increase of 57.94%.
The current valuation score of Transmedics Group Inc is 7.34. Its current P/E ratio is 17.44, which is 12059.84% below the recent high of 2121.04 and 2835.53% above the recent low of -477.16.
The current earnings forecast score of Transmedics Group Inc is 7.69. The average price target is 103.00, with a high of 135.00 and a low of 65.00.
The current price momentum score of Transmedics Group Inc is 3.95. Currently, the stock price is trading between the resistance level at 95.19 and the support level at 80.09, making it suitable for range-bound swing trading.
The current institutional shareholding score of Transmedics Group Inc is 10.00. The latest institutional shareholding proportion is 122.36%, representing a quarter-over-quarter increase of 10.02%. The largest institutional shareholder is Baillie Gifford, holding a total of 267.94K shares, representing 0.02% of shares outstanding, with 25.49% decrease in holdings.
The current risk assessment score of Transmedics Group Inc is 5.50. The company's beta value is 1.94. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.